Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt ...

Over the last several years, drugmakers have agreed to pay $57 billion in opioid settlements, including a landmark $26 ...

Specialist pharma company Mallinckrodt announced on 26 December that it is to acquire Sucampo Pharmaceuticals for around $1.2 billion. The company’s management are clearly looking to bring cheer ...

A $35 billion merger between Capital One and Discover that would make Capital One the nation’s largest credit card issuer cleared a major regulatory hurdle this week, according to multiple ...

Mergers and acquisitions (M&As) are highly anticipated, high-stakes events. When successful, they are one of the fastest ways for organizations to accelerate growth and increase shareholder returns.

Manufacturing problems wreaked havoc with Mallinckrodt's first attempt to secure FDA approval of its treatment candidate terlipressin for hepatorenal syndrome (HRS), but the drugmaker is having ...

Musk’s splashy merger of the social-media company X and his artificial-intelligence startup xAI values the combined company at over $110 billion. That would be a blockbuster deal on Wall Street.